In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revance Therapeutics appoints new CMO

This article was originally published in Scrip

Executive Summary

Revance Therapeutics, a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, has named Arthur P Bertolino executive vice-president and chief medical officer. Dr Bertolino, a Board Certified dermatologist and dermatology industry executive, will join the company on 2 September 2014. Most recently he was vice-president of dermatology for Novartis Institutes for Biomedical Research (NIBR). 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts